002332 仙琚制药
已收盘 07-14 15:00:00
资讯
新帖
简况
仙琚制药最新公告:噻托溴铵吸入喷雾剂药品注册申请获得受理
证券之星 · 07-11
仙琚制药最新公告:噻托溴铵吸入喷雾剂药品注册申请获得受理
仙琚制药:奥美克松钠NDA审评暂停为阶段性标识
证券之星 · 07-08
仙琚制药:奥美克松钠NDA审评暂停为阶段性标识
仙琚制药:截止近期公司股东约4万6千户
证券之星 · 07-08
仙琚制药:截止近期公司股东约4万6千户
仙琚制药:定增项目生产线设备安装调试基本结束
证券之星 · 07-03
仙琚制药:定增项目生产线设备安装调试基本结束
仙琚制药:截止近期公司股东约4万7千户
证券之星 · 06-25
仙琚制药:截止近期公司股东约4万7千户
气溶胶检测概念18日主力净流入1692.67万元,京东方A、仙琚制药居前
金融界 · 06-18
气溶胶检测概念18日主力净流入1692.67万元,京东方A、仙琚制药居前
仙琚制药:公司注册申请芙悦松商标拟用于皮肤科相关产品
证券之星 · 06-17
仙琚制药:公司注册申请芙悦松商标拟用于皮肤科相关产品
【仙琚制药成立新公司 含药品进出口业务】 公开资料显示,近日,浙江仙琚杨府药业有限公司成立,法定代表人为金炜华,经营范围包含:药品生产;药品批发;药品委托生产;药品进出口;药品零售等。股权数据显示,该公司由仙琚制药全资持股。
金融界 · 06-12
【仙琚制药成立新公司 含药品进出口业务】 公开资料显示,近日,浙江仙琚杨府药业有限公司成立,法定代表人为金炜华,经营范围包含:药品生产;药品批发;药品委托生产;药品进出口;药品零售等。股权数据显示,该公司由仙琚制药全资持股。
仙琚制药:截止近期,公司股东约4万7千余户
证券之星 · 06-11
仙琚制药:截止近期,公司股东约4万7千余户
每周股票复盘:仙琚制药(002332)股东户数减少1000户,户均持股增加
证券之星 · 06-06
每周股票复盘:仙琚制药(002332)股东户数减少1000户,户均持股增加
仙琚制药:公司合作开发的改良型新药CZ1S处于三期临床阶段
证券之星 · 06-06
仙琚制药:公司合作开发的改良型新药CZ1S处于三期临床阶段
仙琚制药:截止近期,公司股东约4万7千余户
证券之星 · 06-05
仙琚制药:截止近期,公司股东约4万7千余户
仙琚制药:公司产品非那雄胺片(1mg)适用于治疗男性秃发(雄激素性秃发)
证券之星 · 06-02
仙琚制药:公司产品非那雄胺片(1mg)适用于治疗男性秃发(雄激素性秃发)
仙琚制药:公司生产、研发的主要产品围绕四大治疗领域构建产品群,产品不涉及宠物用药
证券之星 · 05-28
仙琚制药:公司生产、研发的主要产品围绕四大治疗领域构建产品群,产品不涉及宠物用药
每周股票复盘:仙琚制药(002332)股东户数减少,每股派发现金红利3.00元
证券之星 · 05-24
每周股票复盘:仙琚制药(002332)股东户数减少,每股派发现金红利3.00元
仙琚制药:公司持有杭州索元生物医药股份有限公司9.2190%股份
证券之星 · 05-22
仙琚制药:公司持有杭州索元生物医药股份有限公司9.2190%股份
仙琚制药:公司当前主要在高壁垒复杂制剂等改良型新药创新
证券之星 · 05-22
仙琚制药:公司当前主要在高壁垒复杂制剂等改良型新药创新
仙琚制药:屈螺酮炔雌醇片、戊酸雌二醇片已完成绝大多省份的挂网
证券之星 · 05-22
仙琚制药:屈螺酮炔雌醇片、戊酸雌二醇片已完成绝大多省份的挂网
仙琚制药:公司大股东无相关证券出借行为
证券之星 · 05-22
仙琚制药:公司大股东无相关证券出借行为
仙琚制药最新公告:取得黄体酮软胶囊境内生产药品注册证书
证券之星 · 05-21
仙琚制药最新公告:取得黄体酮软胶囊境内生产药品注册证书
加载更多
公司概况
公司名称:
浙江仙琚制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-01-12
主营业务:
浙江仙琚制药股份有限公司的主营业务是甾体原料药和制剂的研制、生产与销售。公司的主要产品是醋酸泼尼松、泼尼松龙、糠酸莫米松、雌二醇、炔雌醇、十一酸睾酮、米非司酮、醋酸甲羟孕酮、维库溴铵、舒更葡糖钠、戊酸雌二醇片、屈螺酮炔雌醇片、十一酸睾酮注射液、黄体酮胶囊(益玛欣)、复方庚酸炔诺酮注射液、左炔诺孕酮肠溶胶囊、米非司酮片、舒更葡糖钠注射液、注射用苯磺顺阿曲库铵、罗库溴铵注射液、注射用维库溴铵、甲磺酸罗哌卡因注射液、糠酸莫米松鼻喷雾剂、噻托溴铵粉雾剂、环索奈德气雾剂。
发行价格:
8.20
{"stockData":{"symbol":"002332","market":"SZ","secType":"STK","nameCN":"仙琚制药","latestPrice":9.61,"timestamp":1752476625000,"preClose":9.52,"halted":0,"volume":14151863,"delay":0,"changeRate":0.0095,"floatShares":985000000,"shares":989000000,"eps":0.3943,"marketStatus":"已收盘","change":0.09,"latestTime":"07-14 15:00:00","open":9.53,"high":9.64,"low":9.5,"amount":136000000,"amplitude":0.0147,"askPrice":9.62,"askSize":1535,"bidPrice":9.61,"bidSize":877,"shortable":0,"etf":0,"ttmEps":0.3943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752543000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.52,"symbolType":"stock","openAndCloseTimeList":[[1752456600000,1752463800000],[1752469200000,1752476400000]],"highLimit":10.47,"lowLimit":8.57,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":989204866,"isCdr":false,"pbRate":1.56,"roa":"--","peRate":24.372305,"roe":"2.42%","epsLYR":0.4,"committee":-0.50608,"marketValue":9506000000,"turnoverRate":0.0144,"status":0,"floatMarketCap":9462000000},"requestUrl":"/m/hq/s/002332","defaultTab":"news","newsList":[{"id":"2550987898","title":"仙琚制药最新公告:噻托溴铵吸入喷雾剂药品注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550987898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550987898?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:17","pubTimestamp":1752221876,"startTime":"0","endTime":"0","summary":"仙琚制药(002332.SZ)公告称,公司于近日收到国家药品监督管理局下发的噻托溴铵吸入喷雾剂境内生产药品注册受理通知书。噻托溴铵吸入喷雾剂规格为每瓶60喷,每喷递送剂量为噻托溴铵2.5μg,药液浓度含噻托溴铵0.2262mg/ml。该品种境内生产药品注册工作进入了审评阶段,如顺利通过审批将丰富公司的产品线,有利于提升公司的市场竞争力。但药品注册审批工作流程有一定时间周期,存在不确定性因素,敬请广大投资者审慎决策,注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100025488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2549141185","title":"仙琚制药:奥美克松钠NDA审评暂停为阶段性标识","url":"https://stock-news.laohu8.com/highlight/detail?id=2549141185","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549141185?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:45","pubTimestamp":1751964330,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,奥美克松钠NDA审评暂停是什么原因?需要补充材料吗?仙琚制药回复:您好,感谢的关注。据了解,在评审期间,“评审状态”会根据评审的程序规则需要予以标识。属于评审的阶段性标识。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800026771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2549196514","title":"仙琚制药:截止近期公司股东约4万6千户","url":"https://stock-news.laohu8.com/highlight/detail?id=2549196514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549196514?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:45","pubTimestamp":1751964326,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司截止7月7日共有多少户股东?仙琚制药回复:您好!截止近期,公司股东约4万6千户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800026763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2548879609","title":"仙琚制药:定增项目生产线设备安装调试基本结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2548879609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548879609?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:30","pubTimestamp":1751531442,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)07月03日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司投资将近7亿的高端制剂基地,年产500万瓶抗胆碱能类吸入剂生产线、年产1200万瓶双动力鼻喷雾剂生产线和年产2500万瓶皮质激素注射剂生产线,请问是否已经调式完毕开始生产?预期能够产生多大的效益?仙琚制药回复:您好,感谢您对公司的关注。公司定增项目生产线设备安装调试基本结束,相关产品工艺验证、产品研发积极推进。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300026262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2546529415","title":"仙琚制药:截止近期公司股东约4万7千户","url":"https://stock-news.laohu8.com/highlight/detail?id=2546529415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546529415?lang=zh_cn&edition=full","pubTime":"2025-06-25 16:36","pubTimestamp":1750840583,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)06月25日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止6月20号,公司的股东人数是多少?谢谢仙琚制药回复:您好!截止近期,公司股东约4万7千户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062500026316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","BK0239","002332"],"gpt_icon":0},{"id":"2544251769","title":"气溶胶检测概念18日主力净流入1692.67万元,京东方A、仙琚制药居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2544251769","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544251769?lang=zh_cn&edition=full","pubTime":"2025-06-18 15:41","pubTimestamp":1750232510,"startTime":"0","endTime":"0","summary":"6月18日,气溶胶检测概念上涨1.02%,今日主力资金流入1692.67万元,概念股6只上涨,4只下跌。主力资金净流入居前的分别为京东方A、仙琚制药、禾信仪器、雪迪龙、理工能科。序号代码名称最新价涨跌幅主力净流入主力净占比1000725京东方A3.950.775745.56万元4.5%2002332仙琚制药9.210.01586.62万元13.74%3688622禾信仪器84.081.71227.34万元4.04%4002658雪迪龙7.17-2.18191.89万元2.0%5002322理工能科11.920.25131.85万元7.41%6300165ST天瑞3.570.85-17.43万元-0.47%7688600皖仪科技23.04-3.44-104.21万元-2.25%8300137ST先河5.8-3.01-130.89万元-3.96%9300862蓝盾光电27.891.05-434.83万元-3.66%10300203聚光科技22.31-1.06-1394.44万元-10.23%","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/18154151144013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002332","SG9999014674.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2544967350","title":"仙琚制药:公司注册申请芙悦松商标拟用于皮肤科相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2544967350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544967350?lang=zh_cn&edition=full","pubTime":"2025-06-17 20:30","pubTimestamp":1750163424,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司申请芙悦松商标,主要经营范围是什么?是否为奥美克松纳上市做准备?仙琚制药回复:您好!感谢您的关注。公司注册申请芙悦松商标,拟用于皮肤科相关产品。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700033514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2542639515","title":"【仙琚制药成立新公司 含药品进出口业务】 公开资料显示,近日,浙江仙琚杨府药业有限公司成立,法定代表人为金炜华,经营范围包含:药品生产;药品批发;药品委托生产;药品进出口;药品零售等。股权数据显示,该公司由仙琚制药全资持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542639515","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542639515?lang=zh_cn&edition=full","pubTime":"2025-06-12 11:27","pubTimestamp":1749698839,"startTime":"0","endTime":"0","summary":"公开资料显示,近日,浙江仙琚杨府药业有限公司成立,法定代表人为金炜华,经营范围包含:药品生产;药品批发;药品委托生产;药品进出口;药品零售等。股权数据显示,该公司由仙琚制药全资持股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/12112751022866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","002332","BK0239","BK0028"],"gpt_icon":0},{"id":"2542532114","title":"仙琚制药:截止近期,公司股东约4万7千余户","url":"https://stock-news.laohu8.com/highlight/detail?id=2542532114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542532114?lang=zh_cn&edition=full","pubTime":"2025-06-11 09:02","pubTimestamp":1749603741,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司截止6月10股东户数有多少户?仙琚制药回复:您好!截止近期,公司股东约4万7千余户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100004654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2541899221","title":"每周股票复盘:仙琚制药(002332)股东户数减少1000户,户均持股增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2541899221","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541899221?lang=zh_cn&edition=full","pubTime":"2025-06-07 07:38","pubTimestamp":1749253094,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘,仙琚制药报收于9.38元,较上周的9.37元上涨0.11%。本周,仙琚制药6月4日盘中最高价报9.67元。仙琚制药当前最新总市值92.79亿元,在化学制药板块市值排名51/150,在两市A股市值排名1698/5148。本周关注点股本股东变化:截至2025年6月4日公司股东户数为4.7万户,较5月26日减少1000.0户股本股东变化近日仙琚制药披露,截至2025年6月4日公司股东户数为4.7万户,较5月26日减少1000.0户,减幅为2.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700008773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2541086180","title":"仙琚制药:公司合作开发的改良型新药CZ1S处于三期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2541086180","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541086180?lang=zh_cn&edition=full","pubTime":"2025-06-06 23:36","pubTimestamp":1749224168,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)06月06日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,请问仙琚制药正在研发中的创新药有几款?在临床几期了?谢谢仙琚制药回复:您好,感谢您的关注。公司近年来处于从仿制药逐步向复杂制剂、改良型新药及创新药的过渡阶段。主要集中在女性健康、下一代吸入制剂、长效制剂等方面。合作开发的改良型新药CZ1S(长效镇痛制剂)处于三期临床阶段,合作开发的1.1类新药奥美克松钠注射液处于申报审批阶段。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600044647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2541304420","title":"仙琚制药:截止近期,公司股东约4万7千余户","url":"https://stock-news.laohu8.com/highlight/detail?id=2541304420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541304420?lang=zh_cn&edition=full","pubTime":"2025-06-05 16:18","pubTimestamp":1749111535,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司截止6.4日共有多少户持股?仙琚制药回复:您好!截止近期,公司股东约4万7千余户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500021958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2540075603","title":"仙琚制药:公司产品非那雄胺片(1mg)适用于治疗男性秃发(雄激素性秃发)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540075603","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540075603?lang=zh_cn&edition=full","pubTime":"2025-06-02 09:54","pubTimestamp":1748829252,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药06月02日在投资者关系平台上答复投资者关心的问题。根据贵司媒体有仙琚非那雄胺1mg 仙琚米诺地尔 TGH洗发水精华这种科学方案,这种方案怎么落地推广与现有多少经销商与我司做好了合作,销量怎么样?公司产品非那雄胺片 适用于治疗男性秃发,该产品已处于正常销售阶段。公司同时引进米诺地尔搽剂等产品,该类产品尚在销售初始阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060200000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002332","SG9999014674.SGD","BK0028"],"gpt_icon":0},{"id":"2538440819","title":"仙琚制药:公司生产、研发的主要产品围绕四大治疗领域构建产品群,产品不涉及宠物用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2538440819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538440819?lang=zh_cn&edition=full","pubTime":"2025-05-28 16:00","pubTimestamp":1748419253,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司作为原料药企是否有涉及宠物用药?请明确回复谢谢仙琚制药回复:您好!公司生产、研发的主要产品围绕皮质激素类药物、性激素类药物、麻醉肌松类药物和呼吸科用药四大治疗领域构建产品群,服务群,产品不涉及宠物用药。感谢您对公司的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052800022303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2537167575","title":"每周股票复盘:仙琚制药(002332)股东户数减少,每股派发现金红利3.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537167575","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537167575?lang=zh_cn&edition=full","pubTime":"2025-05-24 14:47","pubTimestamp":1748069226,"startTime":"0","endTime":"0","summary":"本周关注点股本股东变化:截至2025年5月13日公司股东户数为4.8万户,较5月6日减少2000.0户公司公告汇总:向全体股东每10股派发现金红利人民币3.00元,除权除息日为2025年5月28日股本股东变化近日仙琚制药披露,截至2025年5月13日公司股东户数为4.8万户,较5月6日减少2000.0户,减幅为4.0%。公司公告汇总浙江仙琚制药股份有限公司2024年年度权益分派方案已获2025年5月15日召开的公司2024年年度股东大会审议通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400012690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2537942032","title":"仙琚制药:公司持有杭州索元生物医药股份有限公司9.2190%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2537942032","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537942032?lang=zh_cn&edition=full","pubTime":"2025-05-22 22:12","pubTimestamp":1747923140,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,在贵公司2024年年报其他权益工具投资中发现,索元生物的期末余额为0,请问是贵公司已经不再持股索元生物了吗?仙琚制药回复:您好!感谢您的关注。公司持有杭州索元生物医药股份有限公司9.2190%股份。公司持有对上述公司的股权投资属于非交易性权益工具投资,因此公司将其指定为以公允价值计量且其变动计入其他综合收益的权益工具投资。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200037684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","161726","SG9999014674.SGD","002332","399441"],"gpt_icon":0},{"id":"2537081942","title":"仙琚制药:公司当前主要在高壁垒复杂制剂等改良型新药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2537081942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537081942?lang=zh_cn&edition=full","pubTime":"2025-05-22 22:09","pubTimestamp":1747922958,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药05月22日在投资者关系平台上答复投资者关心的问题。是否能在未来成为公司业绩新的增长点?公司聚焦甾体激素领域,同时以开放的心态关注并探索创新。公司当前主要在高壁垒复杂制剂等改良型新药创新,如吸入制剂、长效制剂等。未来对创新药领域也将从解决临床需求、新药作用机理、化合物及靶点筛选等方面进行探索和布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200037658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","SG9999014674.SGD","BK0239","BK0028"],"gpt_icon":0},{"id":"2537942020","title":"仙琚制药:屈螺酮炔雌醇片、戊酸雌二醇片已完成绝大多省份的挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2537942020","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537942020?lang=zh_cn&edition=full","pubTime":"2025-05-22 22:09","pubTimestamp":1747922957,"startTime":"0","endTime":"0","summary":"请介绍贵司最近一年获批上市的仿制药挂网上市情况和计划:如戊酸雌二醇片,去氧孕烯炔雌醇片,贝前列素钠片,甲泼尼龙片,地屈孕酮片和黄体酮软胶囊。屈螺酮炔雌醇片、戊酸雌二醇片已完成绝大多省份的挂网,2025年一季度保持较好增长。2025年新获批的去氧孕烯炔雌醇片,贝前列素钠片、地屈孕酮片和黄体酮软胶囊等产品公司正在积极推进挂网等相关市场准入工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200037657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0239","BK0028","002332"],"gpt_icon":0},{"id":"2537994229","title":"仙琚制药:公司大股东无相关证券出借行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2537994229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537994229?lang=zh_cn&edition=full","pubTime":"2025-05-22 22:06","pubTimestamp":1747922785,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司或者大股东是否有出借股份融券的行为,如有请说明,谢谢!仙琚制药回复:您好!感谢您的关注。经查询,公司大股东无相关证券出借行为,谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200037644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","SG9999014674.SGD","BK0239","BK0028","161027"],"gpt_icon":0},{"id":"2537029886","title":"仙琚制药最新公告:取得黄体酮软胶囊境内生产药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2537029886","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537029886?lang=zh_cn&edition=full","pubTime":"2025-05-21 16:33","pubTimestamp":1747816410,"startTime":"0","endTime":"0","summary":"仙琚制药(002332.SZ)公告称,公司近日收到国家药品监督管理局核准签发的关于黄体酮软胶囊的《药品注册证书》,公司黄体酮软胶囊被批准注册。黄体酮软胶囊规格为0.1g和0.2g,适应症为用于黄体缺乏引起的机能障碍,有助于妊娠。本次公司的黄体酮软胶囊规格与原研已批准上市的规格一致,按化学药品4类获得批准。公司取得该证书有利于丰富公司的妇科产品线,提升产品组合的市场竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052100026173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","SG9999014674.SGD","002332"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752506913741,"stockEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":-0.001},{"period":"3month","weight":0.0608},{"period":"6month","weight":0.0341},{"period":"1year","weight":-0.1259},{"period":"ytd","weight":-0.0106}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.084},{"period":"6month","weight":0.1078},{"period":"1year","weight":0.1817},{"period":"ytd","weight":0.0473}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江仙琚制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"46000人(较上一季度减少2.13%)","perCapita":"21403股","listingDate":"2010-01-12","address":"浙江省台州市仙居县仙药路1号","registeredCapital":"98920万元","survey":" 浙江仙琚制药股份有限公司的主营业务是甾体原料药和制剂的研制、生产与销售。公司的主要产品是醋酸泼尼松、泼尼松龙、糠酸莫米松、雌二醇、炔雌醇、十一酸睾酮、米非司酮、醋酸甲羟孕酮、维库溴铵、舒更葡糖钠、戊酸雌二醇片、屈螺酮炔雌醇片、十一酸睾酮注射液、黄体酮胶囊(益玛欣)、复方庚酸炔诺酮注射液、左炔诺孕酮肠溶胶囊、米非司酮片、舒更葡糖钠注射液、注射用苯磺顺阿曲库铵、罗库溴铵注射液、注射用维库溴铵、甲磺酸罗哌卡因注射液、糠酸莫米松鼻喷雾剂、噻托溴铵粉雾剂、环索奈德气雾剂。","listedPrice":8.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仙琚制药,002332,仙琚制药股票,仙琚制药股票老虎,仙琚制药股票老虎国际,仙琚制药行情,仙琚制药股票行情,仙琚制药股价,仙琚制药股市,仙琚制药股票价格,仙琚制药股票交易,仙琚制药股票购买,仙琚制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}